AtriCure Inc. (ATRC)

17.21
0.30 1.80
NASDAQ : Health Technology
Prev Close 16.91
Open 16.96
Day Low/High 16.96 / 17.55
52 Wk Low/High 14.88 / 25.18
Volume 204.03K
Avg Volume 173.40K
Exchange NASDAQ
Shares Outstanding 34.47M
Market Cap 584.68M
EPS -1.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

AtriCure is Now Oversold (ATRC)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

AtriCure Reports Preliminary Results For Fourth Quarter And Full Year 2017

AtriCure Reports Preliminary Results For Fourth Quarter And Full Year 2017

AtriCure, Inc. ( Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced preliminary financial results for the fourth quarter and...

AtriCure To Present At The 36th Annual JP Morgan Healthcare Conference

AtriCure To Present At The 36th Annual JP Morgan Healthcare Conference

AtriCure, Inc. ( Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will present at the 36 th Annual JP Morgan...

AtriCure is Now Oversold (ATRC)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ABAX, ATKR, AUTO, BIO.B, BWINB, CNCE, EGY, NWS, RADA, RFP, SBNY, SORL, WDAY, XOMA Downgrades: ATRC, CCR, GPRK, GWRE, HCAP, KODK, SNPS Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

AtriCure To Present At The Piper Jaffray 29th Annual Healthcare Conference

AtriCure To Present At The Piper Jaffray 29th Annual Healthcare Conference

AtriCure, Inc. ( Nasdaq:ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will present at the Piper Jaffray 29 th...

AtriCure Becomes Oversold (ATRC)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

AtriCure Reports Third Quarter 2017 Financial Results

AtriCure Reports Third Quarter 2017 Financial Results

AtriCure, Inc. ( Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced third quarter 2017 financial results.

AtriCure To Present At The Stifel Healthcare Conference

AtriCure To Present At The Stifel Healthcare Conference

AtriCure, Inc. ( Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will present at the Stifel Healthcare...

AtriCure To Announce Third Quarter 2017 Financial Results

AtriCure To Announce Third Quarter 2017 Financial Results

AtriCure, Inc. ( Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its third quarter 2017 financial...

AtriCure Announces U.S. Launch Of The AtriClip® PRO•V™ Device

AtriCure Announces U.S. Launch Of The AtriClip® PRO•V™ Device

AtriCure, Inc. ( Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that it has launched the AtriClip PRO•V™ Left Atrial...

AtriCure To Present At The Morgan Stanley Global Healthcare Conference

AtriCure To Present At The Morgan Stanley Global Healthcare Conference

AtriCure, Inc. ( Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will present at the Morgan Stanley Global...

ATRC Crosses Above Average Analyst Target

In recent trading, shares of AtriCure Inc have crossed above the average analyst 12-month target price of $23.50, changing hands for $23.84/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

AtriCure Reports Second Quarter 2017 Financial Results

AtriCure Reports Second Quarter 2017 Financial Results

AtriCure, Inc. ( Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced second quarter 2017 financial results.

AtriCure To Present At The Canaccord Genuity 37th Annual Growth Conference

AtriCure To Present At The Canaccord Genuity 37th Annual Growth Conference

AtriCure, Inc. ( Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will present at the Canaccord Genuity...

AtriCure Announces Hiring Of Chief Technology Officer

AtriCure Announces Hiring Of Chief Technology Officer

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced it has hired Salvatore (Sam) Privitera as its Chief Technology...

AtriCure To Announce Second Quarter 2017 Financial Results

AtriCure To Announce Second Quarter 2017 Financial Results

AtriCure, Inc. ( Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its second quarter 2017 financial...

ATRC Crosses Above Average Analyst Target

In recent trading, shares of AtriCure Inc have crossed above the average analyst 12-month target price of $22.60, changing hands for $22.69/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

AtriCure To Present At The JMP Securities Life Science Conference

AtriCure, Inc. ( Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will present at the JMP Securities Life...

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ASYS, ATRC, LMIA, MSB, MT, PCOM, SPAR, SVM, TRUE Downgrades: AEL, ASH, ASPS, IMAX, INFN, JCP Initiations: EDIT Read on to get TheStreet Quant Ratings' detailed report:

AtriCure Reports First Quarter 2017 Financial Results

AtriCure, Inc. ( Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced first quarter 2017 financial results.

AtriCure Reaches Analyst Target Price

In recent trading, shares of AtriCure Inc have crossed above the average analyst 12-month target price of $20.75, changing hands for $20.89/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

AtriCure's AtriClip System Surpasses 100,000 Units Sold Worldwide

AtriCure, Inc. ( Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced it has sold more than 100,000 AtriClip ® Left...

AtriCure To Announce First Quarter 2017 Financial Results

AtriCure, Inc. ( Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its first quarter 2017 financial...

AtriCure Names Two New Members To Its Board Of Directors

AtriCure, Inc. ( Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that Regina Groves and B.

AtriCure Names National Principal Investigator For The CONVERGE IDE Clinical Trial

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that it has named Dr.

AtriCure To Present At The Needham & Company's 16th Annual Healthcare Conference

AtriCure, Inc. ( Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will present at the Needham & Company's 16 th...

AtriCure Announces Hiring Of Senior Vice President Of Clinical, Regulatory, And Scientific Affairs

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced it has hired Vinayak (Vini) Doraiswamy, PhD as its Senior Vice...

TheStreet Quant Rating: D+ (Sell)